Health Watch USA meeting to explore how repeated COVID-19 vaccination compares with infection risks in vulnerable kidney patients
United States, 11 February 2026 – Infection prevention continues to evolve as researchers and clinicians learn more about COVID-19, vaccination strategies, and the needs of high-risk populations. One group that requires special attention is patients living with chronic kidney disease, including those undergoing dialysis or living with a kidney transplant.
On February 18, 2026, Health Watch USA will host a timely discussion focused on the effects of repeated COVID-19 vaccinations compared with the impact of COVID-19 infection in patients with kidney disease. The session will be led by Kevin Kavanagh, MD, MS, and feature Christos Argyropoulos, MD, PhD, MS, FASN, a specialist in nephrology.
Patients with kidney disease are more vulnerable to infections due to weakened immune systems. Many also face additional health challenges such as inflammation, cardiovascular risks, and the effects of long-term treatments. For them, COVID-19 can lead to more severe illness and complications. At the same time, questions continue to arise about how repeated vaccinations influence immune response, inflammation, and overall disease progression in this population.
In simple terms, the session will examine two important issues: how COVID-19 infection affects kidney patients and how repeated COVID-19 vaccinations affect them. Experts will review scientific data to understand immune and non-immune effects, including possible impacts on heart health, kidney function, and long-term outcomes. The goal is to look at evidence clearly and carefully, helping healthcare professionals make informed decisions.
For infection prevention specialists, nephrologists, and hospital administrators, the discussion offers practical guidance. It will help shape vaccination strategies in dialysis centers, improve patient communication, and strengthen collaboration between infection control and public health teams. The session also aims to address vaccine misinformation by focusing on clinical research and real-world outcomes.
As healthcare systems prepare for future respiratory virus seasons, protecting medically vulnerable patients remains a priority. Conversations grounded in science are essential for guiding policies and supporting patient safety.
The February 18 meeting serves as a reminder that infection prevention is not only about controlling outbreaks but also about understanding how prevention strategies affect patients with complex chronic conditions. For kidney disease patients, balanced and evidence-based decisions can make a significant difference in health outcomes.